When it comes to psychedelic therapy, music may heighten the benefit. For example, studies have shown that music has the ability to help clear mental distress and potentially help with physical wellness. In fact, music could play a role in studies being conducted by psychedelic companies such as NeonMind Biosciences’ (CSE:NEON) (OTC:NMDBF), Cybin Inc. (NEO:CYBN)(OTC:CLXPF), Mind Medicine Inc. (NEO:MMED)(OTC:MMEDF), Numinus Wellness (TSXV:NUMI)(OTC:LKYSF), and Field Trip Health Ltd. (CSE:FTRP)(OTC:FTRPF).
“Neuroscientist Mendel Kaelen became fascinated by sound at Imperial College London while researching the therapeutic potential of psychedelic drugs such as psilocybin (found in magic mushrooms) to help issues from depression to alcoholism,” reported Elle. “Music was used during the trials and, as a result, Kaelen investigated sound-based therapeutic psychedelic journeys. In 2019, Wavepaths ran an immersive pop-up in London, in which you listened to sound that iterated according to inputs like breathing (to show how relaxed you were). It sold out, and enabled Kaelen to prove his thesis.”
Look at NeonMind Biosciences (CSE:NEON)(OTC:NMDBF) for example
NeonMind Biosciences just announced the commencement of a three phase university study dedicated to creating an ideal music playlist to accompany therapeutic psychedelic sessions. Previous research has established that music for a therapeutic psychedelic session can significantly impact the experience.
“The emotional arc of a musical playlist during a psychedelic session can play an important role in supporting someone’s therapeutic experience,” says Rob Tessarolo, President & CEO of NeonMind. “Music can act as a pathway that is followed throughout the patient’s journey, taking them to places on an emotional level that they wouldn’t necessarily go without it. Working with Dr. Russo and his team means we’re able to scientifically investigate what have to date been assumptions about what makes a good playlist.”
NeonMind is working with Dr. Frank Russo, a professor of Psychology at Ryerson University, who conducts research on the biological, cognitive, and social-emotional bases of music and speech at the Science of Music Auditory Research and Technology (SMART) Lab. He is also an affiliate scientist at the Toronto Rehabilitation Institute, a core member of the McMaster Institute for Music and the Mind, and an adjunct professor at the University of Toronto’s Music and Health Collaboratory.
NeonMind will conduct the research in three phases:
– an online playlist candidate validation study, surveying 50 people with relation to the self-transcendent emotions experienced when listening to snippets of longer musical tracks;
– an in-person playlist validation study at Ryerson’s SMART Lab; and
– a comprehensive in-person physiological validation study measuring biological markers to further substantiate the potential for self-transcendent emotions that the playlist in question generates.
“This is an exciting frontier to be a part of that dovetails nicely with several aspects of research that I’ve been conducting into the psychology of music throughout my career,” says Dr. Russo. “Music without a psychedelic has the potential to generate self-transcendent emotions such as compassion and awe, which may be transformative; on the basis of past research on music and psychedelics, it seems that the music a person listens to during a therapeutic trip is a major determinant of the overall experience. The playlist we are working towards takes various theoretical considerations into account, and the series of studies we’ve designed will enable us to iteratively assess and refine its efficacy.
Each phase will help the team assess and fine-tune the playlist which will then be used in NeonMind’s clinical trials and for the enhancement of psychedelic-assisted psychotherapy services.
Other related developments from around the markets include:
Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, announced key senior management changes to lead the buildout of its development and clinical operations in the United States and Europe. Effective immediately, Alexander Belser, PhD, will serve as Chief Clinical Officer, and Aaron Bartlone will serve as Chief Operating Officer of Cybin US Holdings Inc. The Company also announced that co-founder and former Chief Operating Officer, Paul Glavine will assume the role of Chief Growth Officer of Cybin Inc., and co-founder and former SVP, Business Development, John Kanakis will assume the role of Chief Business Officer.
Mind Medicine Inc., a leading clinical-stage psychedelic medicine biotech company, announced the publication of the first study on MDMA dosing optimization using personalized medicine. The study took place at the University Hospital Basel Liechti Lab, in Basel, Switzerland. This study provides the first scientific data for predicting responses to MDMA and optimizing dosing. This may maximize the potential beneficial therapeutic effects while reducing adverse responses when treating medical conditions.
Numinus Wellness, a company creating an ecosystem of health solutions centered around the safe, evidence-based and accessible use of psychedelic-assisted psychotherapies, is pleased to announce that it has closed a bought deal financing of 28,000,000 units the Company at a price of $1.25 per Unit for total gross proceeds of $35 million. The Offering was conducted by Eight Capital and Canaccord Genuity Corp. The Underwriters also exercised their over-allotment option in full to purchase an additional 4,200,000 Units for additional gross proceeds of $5.25 million. Including the proceeds from the exercise of the over-allotment option, the total gross proceeds of the Offering are $40.25 million with an aggregate of 32,200,000 Units issued.
Field Trip Health Ltd., a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has closed the bought deal short form prospectus offering previously announced on February 25 and 26, 2021, including the full exercise of the underwriters’ over-allotment option. In connection with the Offering, Field Trip issued 14,661,499 common shares, at a price of C$6.50 per Common Share, for aggregate gross proceeds of $95 million. The lead investor in the Offering was Soleus Capital with additional participation by Avidity Partners, Sphera Funds, Pura Vida Investments, Jennison Associates and other healthcare specialized institutional investors.
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. NeonMind Biosciences Inc. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of NeonMind Biosciences Inc.
Please click here for full disclaimer.